Boston Scientific Corp. (NYSE:BSX) set out to compare its new Promus Element drug-eluting stent system with Abbott’s (ABT) Xience Prime.
The BSX-funded study will evaluate coronary revascularization outcomes in a 2,980-patient sample across 50 sites in France, Germany, Italy, Spain and the U.K.
Former iterations of the Promus line were private-label versions of Abbott’s Xience V drug-eluting stents, but the Natick, Mass.-based stent pioneer’s deal to rebrand its rival’s devices ended last year.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
BSX won CE Mark approval for the Promus Element, its third-generation DES model, in October.
The Massachusetts Medical Devices Journal is the online journal of the medical devices industry in the Commonwealth and New England, providing day-to-day coverage of the devices that save lives, the people behind them, and the burgeoning trends and developments within the industry.
